Abstract: |
RATIONALE AND OBJECTIVES To determine if magnetic resonance lymphography performed with subcutaneously administered AMI–227, a nanoparticulate iron oxide contrast agent, can distinguish reactive from tumor–bearing lymph nodes. MATERIALS AND METHODS Mature male Copenhagen rats were inoculated with cell suspensions of R3327–MAT–LyLu rat prostate carcinoma (n = 21) or Freund's complete adjuvant (n = 15) in the left footpad to generate ipsilateral popliteal lymph node metastases or lymphadenitis. At 12 to 14 days after inoculation, T1– and T2–weighted magnetic resonance images of bilateral popliteal areas were obtained before and 24 hours after subcutaneous administration of AMI–227. Contrast–to–noise ratios were calculated in precontrast and postcontrast images. Bilateral popliteal nodes were excised for pathologic assessment. RESULTS AMI–227 resulted in decreased contrast–to–noise ratios in reactive (Tl − W = −7.01 ± 1.13, T2 − W = −31.64 ± 5.35) and normal (T1 − W = −13.56 ± 1.97, T2 − W = −21.62 ± 2.51) nodes. Contrast–to–noise ratios were unchanged (T1 − W = −0.22 ± 1.71, T2 − W = −2.20 ± 4.19) in tumor–containing nodes. These differences in contrast–to–noise ratio changes between tumor–bearing versus nontumor–bearing nodes were statistically significant (P < 0.05). Histologic analysis showed similar distribution of AMI–227 within normal and reactive nodes, but not in tumor–bearing nodes. CONCLUSIONS Differences in AMI–227–uptake between tumor– and nontumor–bearing nodes detected with magnetic resonance imaging are helpful for distinguishing the two entities. © 1995, Lippincott-Raven Publishers. |